Volume 6, Issue 4 (11-2016)                   Iran J Ped Hematol Oncol 2016, 6(4): 228-234 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghassemi A, Badiee Z, Farhangi H, Banihashem A, Syedi S J, Ghodsi R, et al . Evaluation of Efficacy of Varicella Vaccine in Pediatric Patients with Acute lymphoblastic Leukemia . Iran J Ped Hematol Oncol 2016; 6 (4) :228-234
URL: http://ijpho.ssu.ac.ir/article-1-276-en.html
Evaluation of Efficacy of Varicella Vaccine in Pediatric Patients with Acute lymphoblastic Leukemia
Ali Ghassemi * , Zahra Badiee , Hamid Farhangi , Abdolah Banihashem , Seed Javad Syedi , Razie Ghodsi , Abolghassem Mokhtari , Armin Attaranzadeh
Associate Professor of pediatric hematology & oncology, Mashhad University of medical Sciences, Mashhad , Iran
Abstract:   (4384 Views)

Abstract

Background:

Varicella is a highly contagious and dangerous disease especially in immunocompromised patients. Children with cancer are at increased risk of severe illness and may fatal cases occur. Vaccination from VZV ( varicella zoster vaccine) infection can be safe, immunogenic, and effective in children with leukemia who meet the criteria and are at the risk of serious disease or death. The aim of this study was   investigate the efficacy of vaccines VZV on pediatric patients with Acute Lymphoblastic Leukemia

Materials and Methods:

The study was performed on 46 ALL children aged between 1to15 years old who underwent chemotherapy. Considering the efficacy of vaccines on pediatric patients the title serum sample of IgG-anti-VZV avidity was determined using a test kit before and after the injection of vaccines VZV.

Results:

A total of 46 patients were included analysis. Their title serum sample IgG were negative before the injection of  vaccines VZV and after receiving VZV vaccine with respect to title serum sample IgG atatus,  31 (67.4%) patients were positive and 15 (32.6%) patients were negetive. No significant was observed association between either title of IgG-anti-VZV after receiving of VZV vaccine and gender (P = 1.0) title of IgG-anti-VZV and age groups (P =0.387).

Conclusion:  

Regarding the obtained results, it can be concluded that varicella vaccination can have an acceptable effectiveness on pediatric patients with ALL. Varicella vaccination can be recommended for protecting these patients against VZV in order to decrease the morbidity rate caused by this infection. 

Keywords: ALL, children, Varicella Vaccine
Full-Text [PDF 188 kb]   (841 Downloads)    
Type of Study: Research | Subject: Heart
Received: 2016/01/13 | Accepted: 2016/04/26 | Published: 2016/10/30
References
1. Heininger U, Seward JF. Varicella Lancet 2006; 368(9544):1365-76. [Article]
2. Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A, Akdenizli E, et al. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles mumpsrubella vaccination in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27:273–7. [Article]
3. Albrecht MA. Clinical features of varicella-zoster infection: chickenpox. Am Pediatr 2009; 17(2). [Article]
4. Javed F, Utreja A, Bello Correa FO, Al-Askar M, Hudieb M, Qayyum F, et al. Oral health status in children with acute lymphoblastic leukemia. Critical Rev Oncol Hemato 2012; 83 (2012):303–9. [Article]
5. Caniza MA, Hunger SP, Schrauder A, Valsecchi MG, Pui CH, Masera G, The Controversy of Varicella Vaccination in Children with Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 2012; 58(1):12–6. [Article]
6. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987; 80(4):465–472. [Article]
7. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis. 1996; 174 (Suppl 3):S320–3. [Article]
8. Van Tilburg CM, Sanders EAM, Rovers MM, Wolfs TF, Bierings MB. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia 2006; 20:1717–22. [Article]
9. Liese JG, Grote V, Rosenfeld E, Fischer R, Belohradsky BH, v Kries R: The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J 2008; 27(2):119-24. [Article]
10. Feldman S, Hughes WT, Daniel CB: Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975; 56(3):388-97. [Article]
11. National, state, and local area vaccination coverage among children aged 19–35 months-United States, 2006. MMWR 2007; 56(34):880–5. [Article]
12. 12. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008; 122(3):e744–51. [Article]
13. 13. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94:524–6. [Article]
14. 14. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 2002; 287:606–11. [Article]
15. 15. Pourakbari B, Shahbaznezhad L, Parvaneh N, Nikkhah S, Mahmoudi S, Teymuri M, et al. Eroepidemiology of Varicella Zoster Virus among children, adolescents and medical students in a referral children medical center, Tehran, Iran, IRAN. J MICROBIOL 2012; 4 (3):136-8. [Article]
16. Socan M, Berginc N, Lajovic J. Varicella susceptibility and transmission dynamics in Slovenia. BMC Public Health 2010; 10:360. [Article]
17. Cenoz MG, Martínez-Artola V, Guevara M, ezpeleta C, Barricarte A, Castilla J. Effctiveness of one and two doses of varicella vaccine in preventing laboratory-confimed casesin children in Navarre, Spain. Human Vaccin Immunothera 2013; 9(5):1172–6. [Article]
18. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program:a review. J Infect Dis 2008; 197(Suppl 2):S82-9. [Article]
19. Shapiro D, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203(3):312-5. [Article]
20. Vázquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291(7):851-5. [Article]
21. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356(11):1121-9. [Article]
22. American Academy of Pediatrics. Varicella-zoster infections. In: Pickering, LK, Baker, CJ, Kimberlin DW, Long SS, editors. Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 714-727. [Article]
23. Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986; 78(4 pt 2):757–62. [Article]
24. Prucker C, Attarbaschi A, Peters C, et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 2009; 23(7):1264–9. [Article]
25. Prelog M, Schönlaub J, Jeller V, Almanzar G, Höfner K, Gruber S, et al. Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients. Vaccine 2013; 31(20):2420–6. [Article]
26. Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine 2010; 28(19):3278–84. [Article]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb